Abeona Therapeutics (ABEO) Q3 2024 earnings summary

Executive summary

• FDA accepted BLA resubmission for pz-cel in RDEB, setting a PDUFA date of April 29, 2025, with no new clinical trials required and CMC issues addressed after a prior CRL.

• Commercial launch preparations are underway, including onboarding of treatment centers, payor engagement, staff hiring, and facility expansion.

• CMS granted a product-specific ICD-10-PCS code and favorable MS-DRG 018 assignment for Medicare reimbursement, supporting efficient billing and high reimbursement.

• New U.S. patents issued for pz-cel and its transport system, extending IP protection to 2037 and 2040, and a lease was signed for expanded manufacturing capacity.

• Pipeline includes AAV-based gene therapies for ophthalmic diseases, with preclinical programs progressing and a non-exclusive AAV204 capsid agreement with Beacon Therapeutics.

Financial highlights

• Cash, cash equivalents, short-term investments, and restricted cash totaled $110 million as of September 30, 2024, down from $123 million at June 30, 2024.

• Net loss for Q3 2024 was $30.3 million, including a $15.2 million non-cash loss from warrant and derivative liability remeasurement; Q3 2023 net loss was $11.8 million.

• R&D expenses were $8.9 million for Q3 2024, up 25% year-over-year; G&A expenses were $6.4 million, up 54% year-over-year, mainly due to commercial and launch activities.

• No revenue recognized in Q3 2024; $3.5 million in license revenue recognized in Q3 2023 from a milestone payment.

• Net cash used in operating activities was $39.5 million for the nine months ended September 30, 2024; net cash provided by financing activities was $98.8 million.

Outlook and guidance

• Current cash, investments, and credit facility expected to fund operations into 2026, excluding potential pz-cel revenue or PRV proceeds.

• Focus remains on regulatory review and commercial readiness for a potential 2025 U.S. launch of pz-cel, with no new clinical trials required for approval.

• Manufacturing ramp-up expected post-approval, with current capacity supporting up to 10 patient runs per month and plans to expand further within 18–24 months.

• Additional funding may be required for full execution of development and commercialization plans.

• Company expects continued operating losses and negative cash flows as it advances product development and prepares for commercialization.